Search

everythinglearnresearchcommunity

for

Search:↓

The effectiveness of Finasteride/Dutasteride for treating hair loss, and a cautionary tale about potential side effects such as gynecomastia.

A 30-year-old shared their successful hair restoration journey using a combination of liposomal topical finasteride and minoxidil, vitamins, and a second hair transplant in Greece, resulting in life-changing improvements without side effects. The user emphasized the importance of proper research for hair transplant clinics and expressed gratitude for finding an effective treatment protocol.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

A 26-year-old man who had a hair transplant and used minoxidil with good results is now experiencing shedding and considering finasteride. He's concerned about high progesterone and mild erectile dysfunction before starting the treatment.

A 32-year-old shares their one-year experience using dutasteride 0.5 mg and minoxidil for hair loss, noting some progress but still considering a hair transplant for better density. They mention decreased libido as a side effect and discuss the cost and considerations of a hair transplant.

Blocking DHT is not a complete solution for hair loss; instead, altering the scalp's response to DHT may be more effective. Topical finasteride and minoxidil are current treatments, but future approaches may involve bioengineering, gene therapy, and inflammation control.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

A user shared their six-month progress using oral finasteride (1mg) and topical minoxidil (5%) for hair loss, with additional inconsistent microneedling. The combination showed noticeable improvement, and the user microneedles twice a week.